cancer risk with semaglutide New research suggests GLP 1 medications like and tirzepatide, widely used for weight loss and diabetes, may also lower the of several obesity related cancers, including colorectal, endometrial, and breast What to know about new
Description
Beginning a series of XERF treatments during or shortly after a period of significant weight change can help the skin adapt more gracefully, supporting firmness as the body continues to transform
Epub 2014 Jun 6
This study showed that over 2 years, participants treated with semaglutide experienced a significant reduction in body weight (-15.2%) compared to those who received a placebo (-2.6%)
Data source Data came from the TriNetX US Collaborative Network, containing de-identified electronic health records from 66+ healthcare organizations nationwide
Among participants on the 12mg dose, 91.7% achieved at least 10% body weight reduction by week 48
D., Mohan, R., Maliakel, B., & Madhavamenon, K
